NYSE: EBSEmergent Biosolutions Inc Stock
$4.92-0.25 (-4.84%)
Updated Mar 27, 2025
EBS Price
$4.92
Fair Value Price
N/A
Market Cap
$267.34M
52 Week Low
$1.82
52 Week High
$15.10
P/E
-1.37x
P/B
0.55x
P/S
0.49x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.04B
Earnings
-$190.60M
Gross Margin
34.7%
Operating Margin
-6.89%
Profit Margin
-18.3%
Debt to Equity
1.88
Operating Cash Flow
$59M
Beta
1.57
Next Earnings
Apr 29, 2025
Ex-Dividend
N/A
Next Dividend
N/A
EBS Overview
Emergent BioSolutions Inc. is a biopharmaceutical company developing vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and providing medical devices for biodefense purposes. Among the company's products are the controversial BioThrax (Anthrax Vaccine Adsorbed) and Narcan (naloxone) for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals addressing infectious diseases like cholera and typhoid. Emergent BioSolutions was founded on 1998 and is headquartered in Gaithersburg, MD.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine EBS's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
EBS
Ranked#27 of 56
Ranked#27 of 56
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $21.68 | A | |
| $33.53 | A | |
| $4.67 | A |
Be the first to know about important EBS news, forecast changes, insider trades & much more!
EBS News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how EBS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EBS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
EBS is good value based on its book value relative to its share price (0.55x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.22x)
P/B vs Industry Valuation
EBS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more EBS due diligence checks available for Premium users.
Valuation
EBS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.37x
Industry
11.17x
Market
31.08x
EBS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.55x
Industry
2.22x
EBS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EBS's financial health
Profit margin
Revenue
$194.7M
Net Income
-$31.3M
Profit Margin
-16.1%
EBS's Earnings (EBIT) of -$71.90M... subscribe to Premium to read more.
Interest Coverage Financials
EBS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.4B
Liabilities
$906.9M
Debt to equity
1.88
EBS's short-term assets ($598.70M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EBS's long-term liabilities ($744.50M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EBS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
EBS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$79.9M
Investing
$28.6M
Financing
$500.0k
EBS's operating cash flow ($58.70M)... subscribe to Premium to read more.
Debt Coverage Financials
EBS vs Pharmaceutical Stocks
Emergent Biosolutions Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.